Prime Medicine Presents In Vivo Proof-Of-Concept Data Highlighting Interim Preclinical Advances In Its Wilson's Disease Program And The Broad Potential Of Its Universal Liver-Targeted LNP At ESGCT 31st Annual Congress
Portfolio Pulse from Benzinga Newsdesk
Prime Medicine, Inc. presented promising preclinical data on its liver-targeted LNP platform for genetic therapies at the ESGCT Congress. The data showed successful mutation correction in Wilson's Disease and Glycogen Storage Disease Type 1b models, with plans to initiate IND-enabling activities in 2024.
October 24, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prime Medicine presented preclinical data showing the potential of its liver-targeted LNP platform to correct mutations in Wilson's Disease and GSD1b. The company plans to start IND-enabling activities in 2024, with filings expected in 2026.
The presentation of successful preclinical data at a major congress suggests positive progress in Prime Medicine's genetic therapy programs. The timeline for IND-enabling activities and filings indicates a clear path forward, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100